Role of T Follicular Helper Cells in Autoimmune Hemolytic Anemia (TFH in AIHA)
NCT ID: NCT02828670
Last Updated: 2024-07-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
25 participants
OBSERVATIONAL
2016-06-07
2022-02-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
We hypothesize that AIHA is associated with an increase in the number and/or function of TFH, that could participate in the activation of autoreactive B lymphocytes.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Immunopathology of Autoimmune Hemolytic Anemia
NCT02158195
The Significance of Release of T-follicular Helper and T-follicular Regulatory Cells in Autoimmune Haemolytic Anemia Before and After Tratment
NCT04814394
National Longitudinal Cohort of Hematological Diseases- Autoimmune Hemolytic Anemia
NCT07019038
Peripheral Helper T-cells in Common Variable ImmunoDeficiency
NCT07255157
Clinical Characteristics and Treatment Outcomes of Patients With Autoimmune Hemolytic Anemia
NCT03269292
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
patient
blood sample
spleen sample
control
blood sample
spleen sample
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
blood sample
spleen sample
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Hemoglobin \<11 g/dl
* Low haptoglobin level
* Positive direct antiglobulin test (IgG or IgG + complement)
* Reticulocyte count \>120 G/L
* Patients
* naive to treatment for hemolytic anemia or a in relapse
* Older than 18 years
* Able to understand written and spoken French
* Persons who have provided written consent
Control population
* Patients who have given consent
* Patients over 18 years
* Patients with cold agglutinin disease (progressive AIHA and different treatments of warm autoantibody AIHA) can be included as a sub-group of controls
* Patients with non-auto-immune hemolytic anemia (constitutional of enzymatic origin, membrane-related,…) can be included as a sub-group of controls
Exclusion Criteria
* Pregnancy or breast-feeding women
* Adults under guardianship
* Patients with cancer or malignant hemopathy
* Patients with an on-going infection
* Patients treated with corticoids or immunosuppressants
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Universitaire Dijon
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU Dijon Bourgogne
Dijon, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AUDIA APJ 2014
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.